摘要
目的探讨对难治性支原体肺炎患者选择阿奇霉素+甲泼尼龙药物治疗后获得的临床效果。方法选取该院2017年6月-2018年12月收治的72例难治性支原体肺炎患者作为实验对象;数字奇偶法分组后明确各组所用药物;对照组(36例):选择阿奇霉素进行疾病治疗;观察组(36例):选择阿奇霉素+甲泼尼龙进行疾病治疗;对比治疗效果。结果同对照组难治性支原体肺炎患者用药效果(30.56%、61.11%)对比,观察组用药显效率(66.67%)、用药总有效率(94.44%)均呈现出明显提升(χ^2=9.396 1,11.571 4,P<0.05);观察组肺部啰音消失时间为(8.16±1.43)d,咳嗽好转时间为(7.96±1.39)d,体温恢复正常时间为(7.42±1.89)d;对照组肺部啰音消失时间为(13.39±2.19)d,咳嗽好转时间为(11.85±2.17)d,体温恢复正常时间为(11.53±2.39)d;同对照组难治性支原体肺炎患者症状体征缓解时间对比,观察组肺部啰音消失时间、咳嗽好转时间以及体温恢正常时间均呈现出明显缩短(t=11.997 5,9.056 9,8.093 2,P<0.05);治疗前,在实验室指标方面,组间差异无统计学意义(t=0.561 6,0.179 7,0.298 5,P>0.05);治疗后,同对照组难治性支原体肺炎患者实验室指标对比,观察组FDP水平、CRP水平以及TNF-α水平均呈现出明显降低(t=9.528 0,19.000 7,11.441 9,P<0.05);同对照组难治性支原体肺炎患者用药总副反应发生率(5.56%)对比,观察组(8.33%)未呈现出显著差异同对照组难治性支原体肺炎患者用药总不良反应发生率(5.56%)对比,观察组(8.33%)差异无统计学意义(χ^2=0.214 9,P>0.05)。结论难治性支原体肺炎患者在接受治疗期间,甲泼尼龙+阿奇霉素药物的有效应用,对于患者用药显效率、用药总有效率提升,肺部啰音消失时间、咳嗽好转时间以及体温恢正常时间缩短,FDP水平、CRP水平以及TNF-α水平降低,效果明显,最终对于难治性支原体肺炎患者的康复加快,奠定基础。
Objective To investigate the clinical effects of azithromycin + methylprednisolone in patients with refractory mycoplasmal pneumonia. Methods Seventy-two patients with refractory mycoplasmal pneumonia admitted to our hospital from June 2017 to December 2018 were selected as subjects. The digital parity method was used to identify the drugs used in each group. The control group (36 patients): azithromycin was selected for the disease;observation group (36 cases): choose azithromycin + methylprednisolone for disease treatment;compare treatment effect. Results Compared with the control group (30.56% and 61.11%) in the control group, the effective rate of the observation group (66.67%) and the total effective rate of the drug (94.44%) showed a significant increase (χ^2=9.396 1,11.571 4,P<0.05);the disappearance time of lung sound in observation group was (8.16±1.43)d, the time of cough improve ment was (7.96±1.39)d, and the normal temperature of body temperature was (7.42±1.89)d;The disappearance time of lung arpeggio was (13.39±2.19)d, the time of cough improvement was (11.85±2.17)d, and the normal temperature of body temperature was (11.53±2.39) d. The symptom and sign relief time of patients with refractory mycoplasmal pneumonia in the same control group In contrast, the disappearance time of the lungs in the observation group, the time to improve cough and the normal time of body temperature were significantly shortened (t=11.997 5, 9.056 9, 8.093 2,P<0.05);before treatment, in laboratory indicators, differences between groups Not obvious (t=0.561 6, 0.179 7, 0.298 5,P>0.05);after treatment, compared with the laboratory indicators of patients with refractory mycoplasmal pneumonia in the control group, the FDP level, CRP level and TNF-α level of the observation group showed a significant decrease (t=9.528 0, 19.000 7, 11.441 9,P<0.05);compared with the control group, the incidence of total side effects (5.56%) in patients with refractory mycoplasmal pneumonia, the observation group (8.33%) did not show sig
作者
张祥乐
刘凤桥
雷玙
李畏斓
ZHANG Xiang-le;LIU Feng-qiao;LEI Yu;LI Wei-lan(Department of Respiratory Medicine, Xishuangbanna People's Hospital, Jinghong, Yunnan Province, 666100 China)
出处
《世界复合医学》
2019年第6期44-47,共4页
World Journal of Complex Medicine
关键词
阿奇霉素
甲泼尼龙
难治性支原体肺炎
治疗效果
Azithromycin
Methylprednisolone
Refractory mycoplasmal pneumonia
Therapeutic effect
